COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prevention of Unexplained Recurrent Abortion by Enoxaparine (PREFIX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00740545
Recruitment Status : Terminated (Stopped for futility)
First Posted : August 25, 2008
Last Update Posted : March 5, 2015
Information provided by (Responsible Party):
University Hospital, Brest

Brief Summary:
Standard investigations fail to reveal any apparent cause in 50% of the cases of recurrent spontaneous abortion. Prothrombotic mechanisms were initially evoked. Factor V Leiden, Prothrombin G20210A mutation and protein S deficiency are implicated in the meta-analysis of Rey (Lancet).However, they do not account for a large number of miscarriages.Gris JC and coworkers (Blood 2004)carried out an open trial, low-molecular-weight heparin versus low-dose aspirin, in women with one fetal loss and with a constitutional thrombophilic disorder. They conclude for a benefit action of Low-molecular-weight heparin. There is actually no trials concerning women with unexplained recurrent abortions and without known thrombophilia. Nevertheless,aspirin or enoxaparin are often prescribed. It is time to assess these practices. We therefore initiate a multisite, double blind randomized study, enoxaparine versus placebo, in women without known thrombophilia, which experienced unexplained recurrent abortions.

Condition or disease Intervention/treatment Phase
Alive and Viable Births Drug: enoxaparine 40 mg daily Drug: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 258 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées
Study Start Date : April 2007
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: 2 Drug: placebo
Women inject ourselves every days with placebo

Experimental: 1 Drug: enoxaparine 40 mg daily
Women inject ourselves every days with 40 mg of enoxaparine

Primary Outcome Measures :
  1. Alive and Viable Births [ Time Frame: number of born child healthy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women between 18 and 45 years
  • 2 or more consecutive spontaneous abortions before the 15th week of pregnancy
  • Unexplained abortions
  • No maternal or paternal characterized chromosomal aberration
  • No Anti-phospholipid Syndrome
  • No anatomical abnormality possibly responsible for abortion
  • No Factor V Leiden
  • No Prothrombin G20210A mutation
  • No protein S deficiency
  • No protein C deficiency
  • No Anti thrombin 3 deficiency
  • Proved pregnancy

Exclusion Criteria:

  • Contraindications of enoxaparine 4000 U per day
  • Women with risk of venous thromboembolism during pregnancy
  • No regular anticoagulation or antiplatelet treatment
  • Blood Hemoglobin level below 10g/dl
  • Blood platelet level below 150 000/mm3
  • Creatinine clearance below 30ml/mn
  • Anomaly of the coagulation tests
  • No informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00740545

Layout table for location information
Centre Hospitalier Universitaire de Brest
Brest, France, 29609
Centre Hospitalier Régional Universitaire de Caen
Caen, France, 14033
Centre Hospitalier Universitaire de Dijon
Dijon, France, 21079
Centre Hospitalier Bretagne Sud
Lorient, France
Centre Hospitalier Nord Marseille
Marseille, France, 13915
Centre Hospitalier Universitaire de Rouen
Rouen, France, 76031
Centre Hospitalier Universitaire de St Etienne
Saint Etienne, France
Sponsors and Collaborators
University Hospital, Brest
Layout table for investigator information
Principal Investigator: Elisabeth Pasquier, MD Internal Medecine and pneumology department of university hospital of Brest (FRANCE)
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University Hospital, Brest Identifier: NCT00740545    
Other Study ID Numbers: RB06.050
First Posted: August 25, 2008    Key Record Dates
Last Update Posted: March 5, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action